In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development

Anti-drug antibodies (ADAs), specific for biotherapeutic drugs, are associated with reduced serum drug levels and compromised therapeutic response. The impact of ADA on the bioavailability and clinical efficacy of blockbuster anti-hTNF-α monoclonal antibodies is well recognised, especially for adali...

Descripción completa

Detalles Bibliográficos
Autores principales: Ubah, Obinna C., Porter, Andrew J., Barelle, Caroline J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023846/
https://www.ncbi.nlm.nih.gov/pubmed/32090129
http://dx.doi.org/10.1155/2020/7283239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023846/
https://www.ncbi.nlm.nih.gov/pubmed/32090129
http://dx.doi.org/10.1155/2020/7283239

Ejemplares similares